[1]王川,李亚楠,向波,等.婴幼儿血管瘤生活质量专用量表的信度与效度检验及其临床应用[J].临床小儿外科杂志,2019,18(08):635-639,654.[doi:10.3969/j.issn.1671-6353.2019.08.004]
 Wang Chuan,Li Yanan,Xiang Bo,et al.Measuring reliability and validity of a Chinese mandarin version quality-of-life instrument for infantile hemangioma and its clinical application[J].Journal of Clinical Pediatric Surgery,2019,18(08):635-639,654.[doi:10.3969/j.issn.1671-6353.2019.08.004]
点击复制

婴幼儿血管瘤生活质量专用量表的信度与效度检验及其临床应用

参考文献/References:

1 Frieden IJ,Eichenfield LF,Esterly NB,et al.Guidelines of care for hemangiomas of infancy.American Academy of Dermatology Guidelines/Outcomes Committee[J].J Am Acad Dermatol,1997,37(4):631-637.
2 Kilcline C,Frieden IJ.Infantile hemangiomas:How common are they? A systematic review of the medical literature[J].Pediatr Dermatol,2008,25(2):168-173.DOI:10.1111/j.1525-1470.2008.00626.x.
3 Hoornweg MJ,Smeulders MJ.Van der horst CM.Prevalence and characteristics of haemangiomas in young children[J].Ned Tijdschr Geneeskd,2005,149(44):2455-2458.
4 Munden A,Butschek R,Tom WL,et al.Prospective study of infantile haemangiomas:incidence,clinical characteristics and association with placental anomalies[J].B J Dermatol,2014,170(4):907-913.DOI:10.1111/bjd.12804.
5 Chamlin SL,Mancini AJ,Lai J,et al.Development and validation of a Quality-of-Life instrument for infantile hemangiomas[J].J Invest Dermatol,2015,135(6):1533-1539.DOI:10.1038/jid.2015.18.
6 Varni JW,Sherman SA,Burwinkle TM,et al.The PedsQL Family Impact Module:preliminary reliability and validity[J].Health Qual Life Outcomes,2004,2:55.DOI:10.1186/1477-7525-2-55.
7 Chen RQ,Hao YT,Feng LF,et al.The Chinese version of the Pediatric Quality of Life Inventory (TM) (PedsQL (TM)) Family Impact Module:cross-cultural adaptation and psychometric evaluation[J].Health Qual Life Outcomes,2011,910.DOI:10.1186/1477-7525-9-16.
8 Wang C,Li Y,Xiang B,et al.Quality of Life in children with infantile hemangioma:a case control study[J].Health Qual Life Outcomes,2017,15(1):10.DOI:10.1186/s12955-017-0772-z.
9 Wojcicki P,Wojcicka K.Epidemiology,diagnostics and treatment of vascular tumours and malformations[J].Adv Clin Exp Med,2014,23(3):475-484.DOI:10.17219/acem/37149.
10 祝秀丹,葛莉.心得安治疗婴儿血管瘤相关研究进展[J].临床小儿外科杂志,2012,11(06):475-476.DOI:10.3969/j.issn.1671-6353.2012.06.026.Zhu XD,Ge L.Update of research on infantile hemangiomas treated with propanolol[J].J Clin Ped Sur,2012,11(06):475-476.DOI:10.3969/j.issn.1671-6353.2012.06.026.
11 Leaute-Labreze C,Hoeger P,Mazereeuw-Hautier J,et al.A randomized,controlled trial of oral propranolol in infantile hemangioma[J].N Engl J Med,2015,372(8):735-746.DOI:10.1056/NEJMoa1404710.
12 Prey S,Voisard JJ,Delarue A,et al.Safety of propranolol therapy for severe infantile hemangioma[J].JAMA,2016,315(4):413-415.
13 Lawley LP,Siegfried E,Todd JL.Propranolol treatment for hemangioma of infancy:risks and recommendations[J].Pediatr Dermatol,2009,26(5):610-614.DOI:10.1111/j.1525-1470.2009.00975.x.
14 Janmohamed SR,Van Oosterhout M,De Laat PC,et al.Scoring the therapeutic effects of oral propranolol for infantile hemangioma:A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS)[J].J Am Acad Dermatol,2015,73(2):258-263.DOI:10.1016/j.jaad.2015.05.012.
15 Haggstrom AN,Beaumont JL,Lai J,et al.Measuring the severity of infantile hemangiomas instrument development and reliability[J].Arch Dermatol,2012,148(2):197-202.DOI:10.1001/archdermatol.2011.926.
16 Ji Y,Wang Q,Chen SY,et al.Oral atenolol therapy for proliferating infantile hemangioma A prospective study[J].Medicine (Baltimore),2016,95(24):554-560.DOI:10.1097/MD.0000000000003908.
17 Liu LS,Sokoloff D,Antaya RJ.Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas-is it indicated?[J].Pediatr Dermatol,2013,30(5):554-560.DOI:10.1111/pde.12182.
18 Hoornweg MJ,Grootenhuis MA,van der Horst CM.Health-related quality of life and impact of haemangiomas on children and their parents[J].J Plast Reconstr Aesthet Surg,2009,62(10):1265-1271.DOI:10.1016/j.bjps.2008.03.021.
19 Zweegers J,van der Vleuten CJ.The psychosocial impact of an infantile haemangioma on children and their parents[J].Arch Dis Child,2012,97(10):922-926.DOI:10.1136/archdischild-2012-302470.
20 Bauland CG,Luning TH,Smit JM,et al.Untreated hemangiomas:growth pattern and residual lesions[J].Plast Reconstr Surg,2011,127(4):1643-1648.DOI:10.1097/PRS.0b013e318208d2ac.
21 Haggstrom AN,Drolet BA,Baselga E,et al.Prospective study of infantile hemangiomas:clinical characteristics predicting complications and treatment[J].Pediatrics,2006,118(3):882-887.DOI:10.1542/peds.2006-0413.
22 Xu GQ,Lv RR,Zhao ZF,et al.Topical propranolol for treatment of superficial infantile hemangiomas[J].J Am Acad Dermatol,2012,67(6):1210-1213.DOI:10.1016/j.jaad.2012.03.009.
23 Chan H,Mckay C,Adams S,et al.RCT of timolol maleate gel for superficial infantile hemangiomas in 5-to 24-Week-Olds[J].Pediatrics,2013,131(6):1739-1747.DOI:10.1542/peds.2012-3828.
24 Puttgen K,Lucky A,Adams D,et al.Topical timolol maleate treatment of infantile hemangiomas[J].Pediatrics,2016,138(3):e20160355.DOI:10.1542/peds.2016-0355.

相似文献/References:

[1]周启星,杨文,成琦,等.婴儿腮腺血管瘤22例[J].临床小儿外科杂志,2007,6(03):17.
[2]杨恩 刘铭 彭强. 血管瘤血管内皮生长因子受体KDR基因异常甲基化的研究[J].临床小儿外科杂志,2012,11(04):268.
 [J].Journal of Clinical Pediatric Surgery,2012,11(08):268.
[3]徐仙赟 谢琼珺 黄海金. 噻吗洛尔和普萘洛尔体外调控小鼠血管瘤细胞增殖及凋亡作用的比较[J].临床小儿外科杂志,2014,13(02):117.
[4]黄文雅 肖 天 李春旺 邓 敏 金 科.血管瘤并血小板减少综合征介入栓塞治疗的效果分析[J].临床小儿外科杂志,2018,17(01):43.
 Huang Wenya,Xiao Tian,Li Chunwang,et al.Interventional treatment for KasabachMerrit syndrome in children:a report of 7 cases.[J].Journal of Clinical Pediatric Surgery,2018,17(08):43.
[5]高石,赵国强,岳晓洁.儿童指端血管球瘤1例报道并文献复习[J].临床小儿外科杂志,2019,18(07):615.[doi:10.3969/j.issn.1671-6353.2019.07.019]
 Gao Shi,Zhao Guoqiang,Yue Xiaojie.A case report of a fingertip glomus tumor in children and literature review[J].Journal of Clinical Pediatric Surgery,2019,18(08):615.[doi:10.3969/j.issn.1671-6353.2019.07.019]
[6]刘文英.脉管异常类疾病的分类及相关临床问题[J].临床小儿外科杂志,2019,18(08):621.[doi:10.3969/j.issn.1671-6353.2019.08.001]
 Liu Wenying.Classifications and clinical managements of vascular abnormalities[J].Journal of Clinical Pediatric Surgery,2019,18(08):621.[doi:10.3969/j.issn.1671-6353.2019.08.001]
[7]张明,彭强,刘铭.NF-κB因子在普萘洛尔治疗裸鼠血管瘤模型过程中的表达[J].临床小儿外科杂志,2019,18(08):655.[doi:10.3969/j.issn.1671-6353.2019.08.008]
 Zhang Ming,Peng Qiang,Liu Ming.Expression of NF-kappa B in propranolol treatment for infantile hemangioma in nude mice model[J].Journal of Clinical Pediatric Surgery,2019,18(08):655.[doi:10.3969/j.issn.1671-6353.2019.08.008]
[8]树叶,黄文雅,罗勇奇,等.10例婴幼儿卡梅综合征临床特征及治疗经验总结[J].临床小儿外科杂志,2019,18(09):775.[doi:10.3969/j.issn.1671-6353.2019.09.014]
 Shu Ye,Huang Wenya,Luo Yongqi,et al.Summary of clinical features and treatment protocols of 10 infants with Kasabach-Merritt syndrome[J].Journal of Clinical Pediatric Surgery,2019,18(08):775.[doi:10.3969/j.issn.1671-6353.2019.09.014]
[9]王长凤,孙佳丽,吴长华,等.595 nm脉冲染料激光联合噻吗洛尔滴眼液治疗浅表性婴幼儿血管瘤的疗效观察[J].临床小儿外科杂志,2019,18(11):953.[doi:10.3969/j.issn.1671—6353.2019.11.011]
 Wang Changfeng,Sun Jiali,Wu Changhua,et al.Curative efficacy of timolol plus 595nm pulsed dye laser for superficial infantile hemangioma[J].Journal of Clinical Pediatric Surgery,2019,18(08):953.[doi:10.3969/j.issn.1671—6353.2019.11.011]
[10]郑珊.胆道闭锁患儿获得长期生存需要关注的问题[J].临床小儿外科杂志,2020,19(06):469.[doi:10.3969/j.issn.1671-6353.2020.06.001]
 Zheng Shan.Several outstanding issues in long-term survival of children with biliary atresia[J].Journal of Clinical Pediatric Surgery,2020,19(08):469.[doi:10.3969/j.issn.1671-6353.2020.06.001]

备注/Memo

收稿日期:2018-03-11。
基金项目:国家自然科学基金(编号:81401606);四川大学优秀青年学者基金(编号:2015SU04A15)
通讯作者:吉毅,Email:jijiyuanyuan@163.com

更新日期/Last Update: 1900-01-01